Examination of the repurposed agents in the current AD pipeline revealed that DMT trials were chiefly based on agents derived from hematologic-oncologic (tyrosine kinase inhibitors), cardiovascular (angiotensin II receptor antagonists, angiotensin-converting enzyme inhibitors), and neurologic indications (anticonvulsants), as well as diabetes. This evidence concerns the gene ACE and Alzheimer disease.